Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1990 2
1992 2
1993 2
1994 1
1995 1
1996 1
1997 4
1999 1
2001 3
2003 2
2005 2
2006 1
2008 2
2009 2
2010 3
2011 2
2013 4
2014 3
2015 5
2016 5
2017 5
2018 2
2019 3
2020 2
2021 2
2022 1
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Eye irritation.
Eskes C, Bessou S, Bruner L, Curren R, Harbell J, Jones P, Kreiling R, Liebsch M, McNamee P, Pape W, Prinsen MK, Seidle T, Vanparys P, Worth A, Zuang V. Eskes C, et al. Among authors: prinsen mk. Altern Lab Anim. 2005 Jul;33 Suppl 1:47-81. doi: 10.1177/026119290503301s09. Altern Lab Anim. 2005. PMID: 16194141 No abstract available.
Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs.
Henderson NC, Arnold TD, Katamura Y, Giacomini MM, Rodriguez JD, McCarty JH, Pellicoro A, Raschperger E, Betsholtz C, Ruminski PG, Griggs DW, Prinsen MJ, Maher JJ, Iredale JP, Lacy-Hulbert A, Adams RH, Sheppard D. Henderson NC, et al. Among authors: prinsen mj. Nat Med. 2013 Dec;19(12):1617-24. doi: 10.1038/nm.3282. Epub 2013 Nov 10. Nat Med. 2013. PMID: 24216753 Free PMC article.
A proposed eye irritation testing strategy to reduce and replace in vivo studies using Bottom-Up and Top-Down approaches.
Scott L, Eskes C, Hoffmann S, Adriaens E, Alepée N, Bufo M, Clothier R, Facchini D, Faller C, Guest R, Harbell J, Hartung T, Kamp H, Varlet BL, Meloni M, McNamee P, Osborne R, Pape W, Pfannenbecker U, Prinsen M, Seaman C, Spielmann H, Stokes W, Trouba K, Berghe CV, Goethem FV, Vassallo M, Vinardell P, Zuang V. Scott L, et al. Among authors: prinsen m. Toxicol In Vitro. 2010 Feb;24(1):1-9. doi: 10.1016/j.tiv.2009.05.019. Epub 2009 May 31. Toxicol In Vitro. 2010. PMID: 19490935 Review.
Evaluation of aminohydantoins as a novel class of antimalarial agents.
Meyers MJ, Tortorella MD, Xu J, Qin L, He Z, Lang X, Zeng W, Xu W, Qin L, Prinsen MJ, Sverdrup FM, Eickhoff CS, Griggs DW, Oliva J, Ruminski PG, Jacobsen EJ, Campbell MA, Wood DC, Goldberg DE, Liu X, Lu Y, Lu X, Tu Z, Lu X, Ding K, Chen X. Meyers MJ, et al. Among authors: prinsen mj. ACS Med Chem Lett. 2013 Dec 6;5(1):89-93. doi: 10.1021/ml400412x. eCollection 2014 Jan 9. ACS Med Chem Lett. 2013. PMID: 24900778 Free PMC article.
Targeting VLA4 integrin and CXCR2 mobilizes serially repopulating hematopoietic stem cells.
Karpova D, Rettig MP, Ritchey J, Cancilla D, Christ S, Gehrs L, Chendamarai E, Evbuomwan MO, Holt M, Zhang J, Abou-Ezzi G, Celik H, Wiercinska E, Yang W, Gao F, Eissenberg LG, Heier RF, Arnett SD, Meyers MJ, Prinsen MJ, Griggs DW, Trumpp A, Ruminski PG, Morrow DM, Bonig HB, Link DC, DiPersio JF. Karpova D, et al. Among authors: prinsen mj. J Clin Invest. 2019 May 14;129(7):2745-2759. doi: 10.1172/JCI124738. J Clin Invest. 2019. PMID: 31085833 Free PMC article.
Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0.
Grobben Y, de Man J, van Doornmalen AM, Muller M, Willemsen-Seegers N, Vu-Pham D, Mulder WR, Prinsen MBW, de Wit J, Sterrenburg JG, van Cauter F, den Ouden JE, van Altena AM, Massuger LF, Uitdehaag JCM, Buijsman RC, Zaman GJR. Grobben Y, et al. Among authors: prinsen mbw. Front Immunol. 2021 Jan 28;11:609490. doi: 10.3389/fimmu.2020.609490. eCollection 2020. Front Immunol. 2021. PMID: 33584686 Free PMC article.
TTK Inhibitors as a Targeted Therapy for CTNNB1 (β-catenin) Mutant Cancers.
Zaman GJR, de Roos JADM, Libouban MAA, Prinsen MBW, de Man J, Buijsman RC, Uitdehaag JCM. Zaman GJR, et al. Among authors: prinsen mbw. Mol Cancer Ther. 2017 Nov;16(11):2609-2617. doi: 10.1158/1535-7163.MCT-17-0342. Epub 2017 Jul 27. Mol Cancer Ther. 2017. PMID: 28751540
57 results